tradingkey.logo

Astellas & Vir Biotechnology Collaborate To Advance VIR-5500

ReutersFeb 23, 2026 10:56 PM

- Astellas Pharma Inc 4503.T:

  • ASTELLAS PHARMA: CO & VIR BIOTECHNOLOGY ENTERED GLOBAL STRATEGIC COLLABORATION TO ADVANCE VIR-5500 FOR TREATMENT OF PROSTATE CANCER

  • ASTELLAS: CO WILL OBTAIN EXCLUSIVE RIGHTS TO COMMERCIALIZE VIR-5500 EXCLUDING-U.S.

  • ASTELLAS: TO LEAD COMMERCIALIZATION OF VIR-5500 IN THE U.S. WITH VIR BIOTECHNOLOGY RETAINING OPTION TO CO-PROMOTE

  • ASTELLAS: VIR BIOTECHNOLOGY TO GET $335 MILLION IN UPFRONT & NEAR-TERM MILESTONE PAYMENTS, WILL SPLIT U.S. PROFIT/LOSS EQUALLY WITH ASTELLAS

  • ASTELLAS: ELIGIBLE TO RECEIVE UP TO ADDITIONAL $1.37 BILLION IN DEVELOPMENT, REGULATORY & SALES MILESTONES

  • ASTELLAS: UNDER TERMS OF VIR BIOTECHNOLOGY'S LICENSING DEAL WITH SANOFI, A PORTION OF CERTAIN COLLABORATION PROCEEDS WILL BE SHARED WITH SANOFI

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI